The results of a number of clinical studies have shown that the development of anti-IFNα antibodies occurs frequently in patients with chronic hepatitis C or neoplastic disease, treated with either IFNα2a or IFNα2b [149]. Here, IFNA1 is linked to chronic hepatitis C virus infection.